CLINICAL GUIDELINES RADIATION ONCOLOGY

AIM CLINICAL APPROPRIATENESS GUIDELINES FOR RADIATION ONCOLOGY

The foundation of our solution platform for specialty benefits management is our clinical appropriateness guidelines.

AIM Clinical Appropriateness Guidelines for Radiation Oncology are developed through a rigorous process integrating evidence-based literature with expert physician review. Guidelines for radiation therapy, proton beam therapy, and radiopharmaceutical therapy are included below.

AIM Clinical Appropriateness Guidelines for Radiation Oncology

The treatments addressed in the AIM Clinical Appropriateness Guidelines for Radiation Oncology include brachytherapy, intensity-modulated radiation therapy, stereotactic body radiation therapy, and stereotactic radiosurgery.

OPEN THE GUIDELINES FOR RADIATION ONCOLOGY

AIM Clinical Appropriateness Guidelines for Proton Beam Therapy

The treatment addressed in the AIM Clinical Appropriateness Guidelines for Proton Beam Therapy is proton beam therapy, also known as proton radiation therapy or proton radiotherapy.

OPEN THE GUIDELINES FOR PROTON BEAM THERAPY

AIM Clinical Appropriateness Guidelines for Therapeutic Radiopharmaceuticals

The treatments addressed in the AIM Clinical Appropriateness Guidelines for Therapeutic Radiopharmaceuticals include the most commonly used radiopharmaceutical drug therapies for oncologic conditions.

COMING SOON THERAPEUTIC RADIOPHARMACEUTICALS GUIDELINES EFFECTIVE JUNE 1, 2020

 

DELIVERING CANCER CARE SAFELY AMID COVID-19

The COVID-19 pandemic has altered the delivery of cancer care. But clinical appropriateness and safety are still priorities. Our new resource center offers health care’s latest clinical guidance and insights to help ensure both.

VISIT RESOURCE CENTER

 

Trouble viewing the guidelines?

To open our guidelines, your computer needs Adobe Reader, a free and trusted software that allows you to view PDFs.

GET ADOBE READER